Nuva Pharmaceuticals Inc. (NUVPF) 0.3830 $NUVPF
VANC Pharmaceuticals Announces Health Canada Approval for 5 New Generic Molecules and Provides Commercialization Update
Marketwired - Mon May 04, 7:02AM CDT
VANC Pharmaceuticals Inc. (TSX VENTURE: NPH)(OTCQB: NUVPF) ("VANC" or the "Company"
is pleased to announce that it has received Drug Identification Numbers (DIN) from Health Canada for 5 new generic molecules as an initial notice of consent for new drug submissions. These 5 molecules will comprise of 14 dosage forms across various therapeutic categories; including both chronic (long term) therapy and acute (short term) therapy.
NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Provides Corporate Update and Announces $2,000,000 in Proceeds from Warrant Exercises
Marketwired - Thu Mar 12, 2:46PM CDT
VANC Pharmaceuticals Inc. (TSX VENTURE: NPH)(OTCQB: NUVPF) ("VANC" or the "Company", a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that the Company has received $2,000,000 in proceeds from the exercise of warrants.
NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Places Inventory Purchase Order for 30 Generic Molecules
Marketwired - Wed Jan 14, 5:00AM CST
VANC Pharmaceuticals Inc. ("VANC" or the "Company" (TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter ("OTC" markets, is pleased to announce that it has placed inventory purchase orders for 30 generic molecules with leading generic pharmaceutical manufacturing partners. The Company expects delivery of the products in Q2-2015.
NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Receives Health Canada Approval for 7 Additional Generic Molecules
Marketwired - Tue Dec 16, 7:04AM CST
VANC Pharmaceuticals Inc. ("Vanc" or the "Company" (TSX VENTURE: NPH)(OTCQB: NUVPF) is pleased to announce that it has received Notice of Compliance (NOC) from Health Canada for 7 additional generic molecules, bringing the Company's generic portfolio to a total 30 molecules. The Notice of Compliance from Health Canada provides the authorization for Vanc to market and sell the generic molecules in Canada.
NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Closes Oversubscribed Non Brokered Private Placement
Marketwired - Thu Dec 11, 8:03AM CST
VANC Pharmaceuticals Inc. (the "VANC" or "Company" (TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter ("OTC" markets, is pleased to announce that on December 10, 2014 it closed the oversubscribed non brokered private placement of 7,607,332 Units (the "Units" of VANC at a price of $0.15 per Unit for gross proceeds of $1,141,000.00.
NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Announces Drug Establishment License Issued by Health Canada
Marketwired - Wed Dec 10, 8:03AM CST
VANC Pharmaceuticals Inc. (TSX VENTURE: NPH)(OTCQB: NUVPF) ("VANC" or the "Company", a pharmaceutical company focused on the Canadian generic drug and over-the-counter ("OTC" markets, is pleased to announce that the Company has been issued a Drug Establishment License ("DEL" (license number 102220-A) by Health Canada. The license allows the Company to import pharmaceutical products and distribute them within Canada. The import activity covered by the license includes manufacturing pharmaceuticals at the Company's Good Manufacturing Practices ("GMP" compliant foreign site.
NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Announces Conditional Approval of Previously Announced Private Placement
Marketwired - Mon Dec 08, 4:14PM CST
VANC Pharmaceuticals Inc. ("VANC" or the "Company" (TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter ("OTC" markets, is pleased to announce that the TSX Venture Exchange (the "TSXV" has confirmed its conditional acceptance of the private placement announced November 27, 2014 of 7,333,333 units of the Company at a price of $0.15. The Company anticipates the private placement will be oversubscribed. As a result, the Company expects to close the private placement on or about December 10, 2014.
NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Receives NPNs From Health Canada For 4 Products
Marketwired - Wed Nov 19, 4:13PM CST
VANC Pharmaceuticals Inc. ("Vanc" or the "Company" (TSX VENTURE: NPH)(OTCQB: NUVPF) is pleased to announce that it has received Natural Product Number (the "NPN" approvals for: FerroHEME (heme-iron supplement), PEDIA-SAFE drops (multivitamin dietary supplement for infant and children), SennaLax (natural laxative) and T36 Ointment (disinfectant and corticosteroid). The NPN approvals allow Vanc to manufacture, market and sell all 4 products immediately.
NPH.VN: 0.440 (-0.010)
Vanc Pharmaceuticals Receives Health Canada Approval for 22 Generic Molecules
Marketwired - Wed Nov 19, 3:35PM CST
Vanc Pharmaceuticals Inc. ("Vanc" or the "Company" (TSX VENTURE: NPH)(OTCQB: NUVPF) is pleased to announce that it has received Notice of Compliance (NOC) from Health Canada for 22 generic molecules. These 22 molecules will comprise of 51 dosage forms across various therapeutic categories; including both chronic (long term) therapy and acute (short term) therapy. The Notice of Compliance from Health Canada provides the authorization for Vanc to market and sell the generic molecules in Canada.
NPH.VN: 0.440 (-0.010)
Vanc Pharmaceuticals Inc.: OTC Name Change in Effect
Marketwire - Tue Sep 16, 3:43PM CDT
VANC PHARMACEUTICALS INC. (the "Company" or "VANC" (TSX VENTURE: NPH)(OTCQB: NUVPF) is pleased to announce that its name has been changed with the Finance Industry Regulatory Authority in the US from Nuva Pharmaceuticals Inc. to Vanc Pharmaceuticals Inc. The trading symbol remains the same and is NUVPF.
NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Announces Health Canada Approval for 5 New Generic Molecules and Provides Commercialization Update
Marketwired - Mon May 04, 7:02AM CDT
VANC Pharmaceuticals Inc. (TSX VENTURE: NPH)(OTCQB: NUVPF) ("VANC" or the "Company"
is pleased to announce that it has received Drug Identification Numbers (DIN) from Health Canada for 5 new generic molecules as an initial notice of consent for new drug submissions. These 5 molecules will comprise of 14 dosage forms across various therapeutic categories; including both chronic (long term) therapy and acute (short term) therapy. NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Provides Corporate Update and Announces $2,000,000 in Proceeds from Warrant Exercises
Marketwired - Thu Mar 12, 2:46PM CDT
VANC Pharmaceuticals Inc. (TSX VENTURE: NPH)(OTCQB: NUVPF) ("VANC" or the "Company"
, a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, is pleased to announce that the Company has received $2,000,000 in proceeds from the exercise of warrants. NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Places Inventory Purchase Order for 30 Generic Molecules
Marketwired - Wed Jan 14, 5:00AM CST
VANC Pharmaceuticals Inc. ("VANC" or the "Company"
(TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter ("OTC" markets, is pleased to announce that it has placed inventory purchase orders for 30 generic molecules with leading generic pharmaceutical manufacturing partners. The Company expects delivery of the products in Q2-2015. NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Receives Health Canada Approval for 7 Additional Generic Molecules
Marketwired - Tue Dec 16, 7:04AM CST
VANC Pharmaceuticals Inc. ("Vanc" or the "Company"
(TSX VENTURE: NPH)(OTCQB: NUVPF) is pleased to announce that it has received Notice of Compliance (NOC) from Health Canada for 7 additional generic molecules, bringing the Company's generic portfolio to a total 30 molecules. The Notice of Compliance from Health Canada provides the authorization for Vanc to market and sell the generic molecules in Canada. NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Closes Oversubscribed Non Brokered Private Placement
Marketwired - Thu Dec 11, 8:03AM CST
VANC Pharmaceuticals Inc. (the "VANC" or "Company"
(TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter ("OTC" markets, is pleased to announce that on December 10, 2014 it closed the oversubscribed non brokered private placement of 7,607,332 Units (the "Units" of VANC at a price of $0.15 per Unit for gross proceeds of $1,141,000.00. NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Announces Drug Establishment License Issued by Health Canada
Marketwired - Wed Dec 10, 8:03AM CST
VANC Pharmaceuticals Inc. (TSX VENTURE: NPH)(OTCQB: NUVPF) ("VANC" or the "Company"
, a pharmaceutical company focused on the Canadian generic drug and over-the-counter ("OTC" markets, is pleased to announce that the Company has been issued a Drug Establishment License ("DEL" (license number 102220-A) by Health Canada. The license allows the Company to import pharmaceutical products and distribute them within Canada. The import activity covered by the license includes manufacturing pharmaceuticals at the Company's Good Manufacturing Practices ("GMP" compliant foreign site. NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Announces Conditional Approval of Previously Announced Private Placement
Marketwired - Mon Dec 08, 4:14PM CST
VANC Pharmaceuticals Inc. ("VANC" or the "Company"
(TSX VENTURE: NPH)(OTCQB: NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter ("OTC" markets, is pleased to announce that the TSX Venture Exchange (the "TSXV" has confirmed its conditional acceptance of the private placement announced November 27, 2014 of 7,333,333 units of the Company at a price of $0.15. The Company anticipates the private placement will be oversubscribed. As a result, the Company expects to close the private placement on or about December 10, 2014. NPH.VN: 0.440 (-0.010)
VANC Pharmaceuticals Receives NPNs From Health Canada For 4 Products
Marketwired - Wed Nov 19, 4:13PM CST
VANC Pharmaceuticals Inc. ("Vanc" or the "Company"
(TSX VENTURE: NPH)(OTCQB: NUVPF) is pleased to announce that it has received Natural Product Number (the "NPN" approvals for: FerroHEME (heme-iron supplement), PEDIA-SAFE drops (multivitamin dietary supplement for infant and children), SennaLax (natural laxative) and T36 Ointment (disinfectant and corticosteroid). The NPN approvals allow Vanc to manufacture, market and sell all 4 products immediately. NPH.VN: 0.440 (-0.010)
Vanc Pharmaceuticals Receives Health Canada Approval for 22 Generic Molecules
Marketwired - Wed Nov 19, 3:35PM CST
Vanc Pharmaceuticals Inc. ("Vanc" or the "Company"
(TSX VENTURE: NPH)(OTCQB: NUVPF) is pleased to announce that it has received Notice of Compliance (NOC) from Health Canada for 22 generic molecules. These 22 molecules will comprise of 51 dosage forms across various therapeutic categories; including both chronic (long term) therapy and acute (short term) therapy. The Notice of Compliance from Health Canada provides the authorization for Vanc to market and sell the generic molecules in Canada. NPH.VN: 0.440 (-0.010)
Vanc Pharmaceuticals Inc.: OTC Name Change in Effect
Marketwire - Tue Sep 16, 3:43PM CDT
VANC PHARMACEUTICALS INC. (the "Company" or "VANC"
(TSX VENTURE: NPH)(OTCQB: NUVPF) is pleased to announce that its name has been changed with the Finance Industry Regulatory Authority in the US from Nuva Pharmaceuticals Inc. to Vanc Pharmaceuticals Inc. The trading symbol remains the same and is NUVPF. NPH.VN: 0.440 (-0.010)
